Survival Rates for Uterine Sarcoma

Survival rates can give you an idea of what percentage of people with the same type and stage of cancer are still alive a certain amount of time (usually 5 years) after they were diagnosed. They can’t tell you how long you will live, but they may help give you a better understanding of how likely it is that your treatment will be successful.

Keep in mind that survival rates are estimates and are often based on previous outcomes of large numbers of people who had a specific cancer, but they can’t predict what will happen in any particular person’s case. These statistics can be confusing and may lead you to have more questions. Talk with your doctor about how these numbers may apply to you, as he or she is familiar with your situation.

What is a 5-year relative survival rate?

A relative survival rate compares people with the same type and stage of uterine sarcoma to people in the overall population. For example, if the 5-year relative survival rate for a specific stage of uterine sarcoma is 90%, it means that people who have that cancer are, on average, about 90% as likely as people who don’t have that cancer to live for at least 5 years after being diagnosed.

Where do these numbers come from?

The American Cancer Society relies on information from the SEER* database, maintained by the National Cancer Institute (NCI), to provide survival statistics for different types of cancer.

The SEER database tracks 5-year relative survival rates for uterine sarcoma in the United States, based on how far the cancer has spread. The SEER database, however, does not group cancers by FIGO or AJCC TNM stages (stage 1, stage 2, stage 3, etc.). Instead, it groups cancers into localized, regional, and distant stages:

  • Localized: There is no sign that the cancer has spread outside of the uterus.
  • Regional: The cancer has spread outside the uterus to nearby structures or lymph nodes.
  • Distant: The cancer has spread to distant parts of the body such as the lungs, liver, or bones.

5-year relative survival rates for uterine sarcoma

These numbers are based on women diagnosed with uterine sarcoma between 2008 and 2014.

Leiomyosarcoma

SEER Stage

5-Year Relative Survival Rate

Localized

64%

Regional

35%

Distant

13%

All SEER stages combined 41%

Undifferentiated sarcoma

SEER Stage

5-Year Relative Survival Rate

Localized

68%

Regional

48%

Distant

20%

All SEER stages combined 46%

Endometrial stromal sarcoma*

SEER Stage

5-Year Relative Survival Rate

Localized

98%

Regional

91%

Distant

67%

All SEER stages combined 93%

*The outlook for high-grade ESS tends to be worse than for low-grade ESS, and is more likely to be similar to that for undifferentiated sarcoma (see table above).

Understanding the numbers

  • These numbers apply only to the stage of the cancer when it is first diagnosed. They do not apply later on if the cancer grows, spreads, or comes back after treatment.
  • These numbers don’t take everything into account. Survival rates are grouped based on how far the cancer has spread, but your age, overall health, tumor grade, tumor type, how well the cancer responds to treatment, and other factors can also affect your outlook.
  • People now being diagnosed with uterine sarcoma may have a better outlook than these numbers show. Treatments improve over time, and these numbers are based on people who were diagnosed and treated at least five years earlier.

*SEER= Surveillance, Epidemiology, and End Results

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as journalists, editors, and translators with extensive experience in medical writing.

Gaillard S, Alvarez Secord A. Staging, treatment, and prognosis of endometrial stromal sarcoma and related tumors and uterine adenosarcoma. UpToDate. 2019. Accessed at https://www.uptodate.com/contents/staging-treatment-and-prognosis-of-endometrial-stromal-sarcoma-and-related-tumors-and-uterine-adenosarcoma on October 10, 2019.

Noone AM, Howlader N, Krapcho M, Miller D, Brest A, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2015, National Cancer Institute. Bethesda, MD, https://seer.cancer.gov/csr/1975_2015/, based on November 2017 SEER data submission, posted to the SEER web site, April 2018.

Last Medical Review: October 12, 2017 Last Revised: October 10, 2019

American Cancer Society medical information is copyrighted material. For reprint requests, please see our Content Usage Policy.